Piramal Pharma aims to achieve $2 billion in revenue by 2030, driven by its three key segments: contract development and manufacturing (CDMO), complex hospital generics, and consumer healthcare.
A major factor in the brand’s CDMO business is the company’s capacity to serve customers globally, particularly in both the East and West, without relying on China.
Currently, the CDMO segment accounts for 58% of Piramal Pharma’s revenue. For the fiscal year ending March 31, 2024, the company reported a total revenue of ₹8,171 crore.
By 2030, the CDMO division is projected to generate $1.2 billion in revenue with a 25% EBITDA margin, while the complex hospital generics and consumer healthcare segments are expected to contribute $600 million and $200 million, respectively, also with strong EBITDA margins. As reported by thehindubusinessline.com, the company also plans to reduce its current net debt, which stands at ₹4,000 crore.
